指南与共识神经肿瘤小儿神经外科与脑积水

Von Hippel-Lindau病儿科患者中枢神经系统血管母细胞瘤的筛查与监测建议

Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease.
指南 / 共识 · J Neurooncol · 2024-04-22

该研究基于1992至2023年单中心99例儿科VHL患者回顾性分析,42例发生中枢神经系统血管母细胞瘤,18例接受手术(首次手术平均年龄14.9±1.9岁)。截短型VHL突变携带者肿瘤显现率(HR=3.7,95%CI 1.9-7.4,p<0.0001)和手术率(HR=3.3,95%CI 1.2-8.9,p=0.02)显著高于错义突变携带者。作者建议12岁开始MRI筛查,根据中枢神经系统受累情况每(1-)2年复查。

要点

  • 建议12岁开始MRI筛查,根据中枢神经系统受累情况每(1-)2年复查。
  • 截短型VHL突变携带者肿瘤显现和手术风险显著高于错义突变携带者。
  • 应对受累家庭定期教育肿瘤相关症状,以便及时MRI检查和干预。

核心结论

  • 作者建议12岁开始MRI筛查,根据中枢神经系统受累情况每(1-)2年复查,并特别关注截短型变异患者。
  • 应对受累家庭定期教育潜在肿瘤相关症状,以便及时MRI检查和最终干预,因为中枢神经系统血管母细胞瘤可能在筛查开始前发生。

研究设计与样本

  • 回顾性分析1992至2023年单中心99例儿科VHL患者队列,收集临床、手术、遗传和影像数据并进行统计分析。
  • 德国临床试验注册号DRKS00029553,注册日期2022年8月16日,回顾性注册。

主要发现

  • 42例患者(50%男性)发生中枢神经系统血管母细胞瘤,其中18例(56%男性)接受血管母细胞瘤手术,首次手术平均年龄14.9±1.9岁(范围10.2-17岁)。
  • 首例无症状患者因肿瘤进展在13.2岁时接受手术。
  • 截短型VHL突变携带者较错义突变携带者肿瘤显现率显著更高(HR=3.7,95%CI 1.9-7.4,p<0.0001),手术率显著更高(HR=3.3,95%CI 1.2-8.9,p=0.02)。

关键数值与推荐

  • 推荐12岁开始MRI筛查,检查间隔每(1-)2年,取决于中枢神经系统受累情况。
  • 特别关注截短型变异患者。

临床怎么用

  • 作者建议12岁开始MRI筛查,根据中枢神经系统受累情况每(1-)2年复查。
  • 作者建议特别关注截短型变异患者。
  • 作者建议对受累家庭定期教育潜在肿瘤相关症状,以便及时MRI检查和最终干预。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Von Hippel-Lindau (VHL) disease is an autosomal-dominantly inherited tumor predisposition syndrome. One of the most common tumors are central nervous system (CNS) hemangioblastomas. Recommendations on the initiation and continuation of the screening and surveillance program for CNS tumors in pediatric VHL patients are based on small case series and thus low evidence level. To derive more robust screening recommendations, we report on the largest monocentric pediatric cohort of VHL patients. METHODS: We performed a retrospective analysis on a pediatric cohort of 99 VHL patients consulted at our VHL center from 1992 to 2023. Clinical, surgical, genetic, and imaging data were collected and statistically analyzed. RESULTS: 42 patients (50% male) developed CNS hemangioblastomas, of whom 18 patients (56% male) underwent hemangioblastoma surgery (mean age at first surgery: 14.9 ± 1.9 years; range 10.2-17). The first asymptomatic patient was operated on at the age of 13.2 years due to tumor progress. Truncating VHL mutation carriers had a significantly higher manifestation rate (HR = 3.7, 95% CI: 1.9-7.4, p < 0.0001) and surgery rate (HR = 3.3, 95% CI: 1.2-8.9, p = 0.02) compared with missense mutation carriers. CONCLUSION: We recommend starting MRI imaging at the age of 12 years with examination intervals every (1-) 2 years depending on CNS involvement. Special attention should be paid to patients with truncating variants. Affected families should be educated regularly on potential tumor-associated symptoms to enable timely MRI imaging and eventually intervention, as CNS hemangioblastoma may develop before screening begins. GERMAN CLINICAL TRIALS REGISTER REGISTRATION NUMBER: DRKS00029553, date of registration 08/16/2022, retrospectively registered.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Knoblauch AL, Blaß BI, Steiert C, et al. Screening and surveillance recommendations for central nervous system hemangioblastomas in pediatric patients with Von Hippel-Lindau disease. J Neurooncol. 2024. PMID: 38647646. doi:10.1007/s11060-024-04676-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。